Overview
We are interested in learning how guanfacine immediate release (GIR) acts in the bodies of children with Down syndrome to treat hyperactivity, inattention, or impulsivity. This study aims to understand the safest and most effective dose of GIR for children with Down syndrome. No cost to participants.
Eligibility
InclusionChildren with Down syndrome ages 6-12; non-mosaic DS; hyperactivity, inattention, or impulsivity; meet additional eligibility criteria
Location
Kennedy Krieger Institute
Sponsor & Collaborators
SponsorPediatric Trials Network
Study Flyer
